Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

N/A

2(40.0%)

5Total

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05866419Not ApplicableRecruiting

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

Role: lead

NCT06555419Phase 1Recruiting

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

Role: collaborator

NCT03770572Phase 1Active Not Recruiting

Gene Therapy for Children With CLN3 Batten Disease

Role: lead

NCT03178032Phase 1Completed

Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas

Role: collaborator

NCT02651337Not ApplicableCompleted

Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters

Role: lead

All 5 trials loaded